Kristl C.
- Country
- Belgium
- Department
- Department of Neurology, Neuromuscular Reference Centre (NMRC)
Research Overview
- Phase 2a Study to Evaluate the Safety and Efficacy of Empasiprubart as Add-on Therapy to Efgartigimod in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Efficacy and Safety of DYNE-101 in Participants with Myotonic Dystrophy Type 1: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
- Open-label extension study of KL1333 for long-term safety, tolerability, and efficacy in adults with primary mitochondrial disease
Data & Insights
Has run more than one trial at 225 of 345 partner sites.
Specializations
Neuromuscular Disorders
Specializing in the investigation of generalized myasthenia gravis (gMG), focusing on innovative therapeutic approaches for this chronic autoimmune neuromuscular disorder.
- Autoimmune neuromuscular junction disorders
- Activities of daily living assessment in gMG
- Novel biological therapies for gMG
Evaluates treatment efficacy through standardized assessment tools including the MG-ADL scale.
Therapeutic Development
Conducts research on targeted immunological treatments for autoimmune conditions, with particular emphasis on intravenous therapeutic applications.
- Monoclonal antibody therapies
- Intravenous treatment modalities
- Clinical efficacy assessment
Explores the potential of new biological agents in treating neuromuscular disorders.
Clinical Assessment
Specializes in evaluating treatment outcomes in neuromuscular conditions, utilizing comprehensive clinical assessment methodologies.
- Patient functionality measures
- Quality of life assessment
- Treatment response monitoring
Focuses on measuring therapeutic efficacy through validated clinical assessment tools.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.